| Added by | André Pèlegrin |
|---|---|
| Last modified by | standudu |
| Group name | EquipeAP |
| Item Type | Journal Article |
| Title | HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models |
| Creator | Thomas et al. |
| Author | Gaëlle Thomas |
| Author | Thierry Chardès |
| Author | Nadège Gaborit |
| Author | Caroline Mollevi |
| Author | Wilhem Leconet |
| Author | Bruno Robert |
| Author | Nina Radosevic-Robin |
| Author | Frédérique Penault-Llorca |
| Author | Céline Gongora |
| Author | Pierre-Emmanuel Colombo |
| Author | Yassamine Lazrek |
| Author | Ariel Savina |
| Author | David Azria |
| Author | Hervé Bazin |
| Author | André Pèlegrin |
| Author | Christel Larbouret |
| Abstract | The anti-HER2 antibody pertuzumab inhibits HER2 dimerization and affects HER2/HER3 dimer formation and signaling. As HER3 and its ligand neuregulin are implicated in pancreatic tumorigenesis, we investigated whether HER3 expression could be a predictive biomarker of pertuzumab efficacy in HER2low-expressing pancreatic cancer. We correlated in vitro and in vivo HER3 expression and neuregulin dependency with the inhibitory effect of pertuzumab on cell viability and tumor progression. HER3 knockdown in BxPC-3 cells led to resistance to pertuzumab therapy. Pertuzumab treatment of HER3-expressing pancreatic cancer cells increased HER3 at the cell membrane, whereas the anti-HER3 monoclonal antibody 9F7-F11 down-regulated it. Both antibodies blocked HER3 and AKT phosphorylation and inhibited HER2/HER3 heterodimerization but affected differently HER2 and HER3 homodimers. The pertuzumab/9F7-F11 combination enhanced tumor inhibition and the median survival time in mice xenografted with HER3-expressing pancreatic cancer cells. Finally, HER2 and HER3 were co-expressed in 11% and HER3 alone in 27% of the 45 pancreatic ductal adenocarcinomas analyzed by immunohistochemistry. HER3 is essential for pertuzumab efficacy in HER2low-expressing pancreatic cancer and HER3 expression might be a predictive biomarker of pertuzumab efficacy in such cancers. Further studies in clinical samples are required to confirm these findings and the interest of combining anti-HER2 and anti-HER3 therapeutic antibodies. |
| Publication | Oncotarget |
| Volume | 5 |
| Issue | 16 |
| Pages | 7138-7148 |
| Date | Aug 30, 2014 |
| Journal Abbr | Oncotarget |
| Language | eng |
| ISSN | 1949-2553 |
| Short Title | HER3 as biomarker and therapeutic target in pancreatic cancer |
| Library Catalog | NCBI PubMed |
| Extra | PMID: 25216528 PMCID: PMC4196190 |
| Tags | Equipe, original |
| Date Added | 2019/12/12 - 17:42:38 |
| Date Modified | 2020/01/09 - 18:10:19 |
| Notes and Attachments | Oncotarget_5_7138_Thomas_G.pdf (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
